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background: Current definition of the metabolic syndrome (MetS) is intended to identify individuals with multiple cardiovascular risk factors 
related to insulin resistance and central obesity. However, many centrally obese individuals featuring insulin resistance do not meet current criteria 
for MetS diagnosis. Recently, glycated hemoglobin (HbA1c) measurement has become widely available in clinical practice, allowing a more accurate 
assessment of glucose metabolism. We studied HbA1c reliability as a new diagnostic criterion for MetS and its role in reclassifying asymptomatic 
individuals.
methods: We evaluated 2,357 consecutive subjects (mean age: 43.6 years, 21% female) who underwent a check-up protocol between 2012 
and 2013. All the components of the MetS were routinely assessed, as well as Framingham Risk Score (FRS), C-reactive protein, and HbA1c levels. 
Hepatic steatosis (HS) was identified by ultrasound. Three different models were considered for MetS definition: A (harmonized definition), B (“fasting 
glucose ≥100mg/dL” replaced by “HbA1c ≥5.6%”) and C (composite criterion: “fasting glucose ≥100mg/dL and/or HbA1c ≥5.6%”). Sensitivity, 
specificity and predictive values for the presence of HS, subclinical inflammation (SI) and FRS ≥ 10 % were compared between the models.
results: After adjustment by each of the traditional MetS criteria, HbA1c >5.6% remained an independent predictor of HS (OR 1.7 , CI 1:38 to 
2:10 , p<0.001); SI (OR 1.7 , CI 1.10-1.62 , p=0.004) and FRS ≥10 % (OR 2.9 , CI 2.17-3.79 , p<0.001). Prevalence of MetS was 21.8%, 26.4% and 
27.3% according to models A, B and C, respectively. Model C reclassified 5.5 % of the entire population (N=129) and led to a 25% relative increase 
in MetS prevalence, retaining higher sensitivity than traditional definition with regard to HS (52% vs 43%), SI (39% vs 31%) and FRS ≥10% (66 % vs 
55%). There was no significant difference in specificity and predictive values between the models.
conclusion: HbA1c is an independent predictor of HS, SI, and FRS ≥10%. Its inclusion in MetS definition allows to properly reclassify a significant 
number of individuals.
